Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include: Alopecia universalis, Alopecia totalis, Patchy alopecia, and Alopecia of scalp.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 4 | Alopecia universalis, Alopecia totalis, Patchy alopecia |
Biomarker and diagnostic research for alopecia areata 2 has been reported in the published literature.
No clinical trials have been registered for alopecia areata 2.
240 publications have been identified in PubMed for alopecia areata 2. Research spans Review / Meta-Analysis (33%), Epidemiology / Natural History (24%), and Clinical Trial Publication (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 79 | 33% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
58 |
24% |
Clinical study results | 48 | 20% |
Laboratory research | 28 | 12% |
Patient case studies | 11 | 5% |
New treatment approaches | 7 | 3% |
Other research | 5 | 2% |
Testing and diagnosis research | 4 | 2% |
Harries MJ (2026). [PMID: 41234147](https://pubmed.ncbi.nlm.nih.gov/41234147/). *Br J Dermatol*. [Review / Meta-Analysis]
Shin JM (2026). [PMID: 41942382](https://pubmed.ncbi.nlm.nih.gov/41942382/). *Ann Dermatol*. [Review / Meta-Analysis]
Mauer J (2026). [PMID: 41005700](https://pubmed.ncbi.nlm.nih.gov/41005700/). *Value Health*. [Clinical Trial Publication]
van Caelenberg E (2026). [PMID: 41593007](https://pubmed.ncbi.nlm.nih.gov/41593007/). *Clin Exp Dermatol*. [Basic Science / Preclinical]
Fhager J (2026). [PMID: 41923964](https://pubmed.ncbi.nlm.nih.gov/41923964/). *Skin Health Dis*. [Epidemiology / Natural History]
Blume-Peytavi U (2026). [PMID: 40668972](https://pubmed.ncbi.nlm.nih.gov/40668972/). *Br J Dermatol*. [Clinical Trial Publication]
Sung JH (2026). [PMID: 42064044](https://pubmed.ncbi.nlm.nih.gov/42064044/). *Front Immunol*. [Review / Meta-Analysis]
Potter CS (2026). [PMID: 42011377](https://pubmed.ncbi.nlm.nih.gov/42011377/). *JID Innov*. [Basic Science / Preclinical]
Xiao XP (2026). [PMID: 41517761](https://pubmed.ncbi.nlm.nih.gov/41517761/). *Medicine (Baltimore)*. [Epidemiology / Natural History]
Kearney CA (2026). [PMID: 41714473](https://pubmed.ncbi.nlm.nih.gov/41714473/). *Am J Clin Dermatol*. [Review / Meta-Analysis]
AI-curated news mentioning alopecia areata 2
Updated Jul 25, 2026
A 4.5-year retrospective cohort study evaluates the safety of JAK inhibitors in patients with atopic dermatitis and alopecia areata. The findings contribute to understanding the long-term effects of these treatments in real-world settings.
PRAC has agreed on new safety information regarding desogestrel- and etonogestrel-containing contraceptives and Litfulo for alopecia areata. This meeting highlights ongoing pharmacovigilance efforts but does not indicate any new approvals or significant changes.
MHRA has approved deuruxolitinib for adults suffering from severe alopecia areata, a condition characterized by extensive hair loss. This approval marks a significant advancement in treatment options for patients affected by this autoimmune disorder.